Ramy Rahmé

1.1k total citations
12 papers, 268 citations indexed

About

Ramy Rahmé is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Ramy Rahmé has authored 12 papers receiving a total of 268 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Hematology, 6 papers in Molecular Biology and 3 papers in Genetics. Recurrent topics in Ramy Rahmé's work include Acute Myeloid Leukemia Research (9 papers), Chronic Myeloid Leukemia Treatments (3 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (2 papers). Ramy Rahmé is often cited by papers focused on Acute Myeloid Leukemia Research (9 papers), Chronic Myeloid Leukemia Treatments (3 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (2 papers). Ramy Rahmé collaborates with scholars based in France, United States and Japan. Ramy Rahmé's co-authors include Pierre Fenaux, Lionel Adès, Jean Soulier, Nadia Vasquez, Régis Peffault de Latour, Anna Raimbault, Emmanuelle Clappier, Marie Sébert, Flore Sicre de Fontbrune and Raphaël Itzykson and has published in prestigious journals such as Blood, EMBO Reports and British Journal of Haematology.

In The Last Decade

Ramy Rahmé

10 papers receiving 267 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ramy Rahmé France	4	201	135	63	48	40	12	268
A Dufour Germany	6	212 1.1×	149 1.1×	81 1.3×	59 1.2×	32 0.8×	6	295
Torsten Haferlach Germany	3	177 0.9×	106 0.8×	44 0.7×	77 1.6×	37 0.9×	8	235
Mahesh Swaminathan United States	8	172 0.9×	111 0.8×	81 1.3×	30 0.6×	45 1.1×	31	239
Purvi M. Kakadia Germany	10	208 1.0×	195 1.4×	92 1.5×	41 0.9×	46 1.1×	28	349
Sally Jeffries United Kingdom	6	183 0.9×	66 0.5×	57 0.9×	50 1.0×	25 0.6×	10	235
Giulia Falconi Italy	13	281 1.4×	189 1.4×	124 2.0×	30 0.6×	46 1.1×	28	369
Mariam Ibáñez Spain	9	182 0.9×	245 1.8×	32 0.5×	46 1.0×	49 1.2×	28	339
Amanda R. Leonti United States	8	113 0.6×	99 0.7×	36 0.6×	33 0.7×	55 1.4×	32	193
Zinia J. Kwidama Netherlands	10	230 1.1×	138 1.0×	50 0.8×	60 1.3×	53 1.3×	13	297
Sue Naim United States	5	134 0.7×	233 1.7×	27 0.4×	29 0.6×	43 1.1×	8	299

Countries citing papers authored by Ramy Rahmé

Since Specialization

Citations

This map shows the geographic impact of Ramy Rahmé's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ramy Rahmé with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ramy Rahmé more than expected).

Fields of papers citing papers by Ramy Rahmé

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ramy Rahmé. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ramy Rahmé. The network helps show where Ramy Rahmé may publish in the future.

Co-authorship network of co-authors of Ramy Rahmé

This figure shows the co-authorship network connecting the top 25 collaborators of Ramy Rahmé. A scholar is included among the top collaborators of Ramy Rahmé based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ramy Rahmé. Ramy Rahmé is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Hueso, Thomas, Grégory Lazarian, Adrien Chauchet, et al.. (2025). Bortezomib, Rituximab and Dexamethasone Regimen (BDR) in Waldenström Macroglobulinaemia: A Retrospective Real‐World Analysis. eJHaem. 6(2). e70019–e70019.

Rahmé, Ramy, et al.. (2025). Mutant p53 regulates a distinct gene set by a mode of genome occupancy that is shared with wild type. EMBO Reports. 26(5). 1315–1343. 1 indexed citations

Rahmé, Ramy & Thorsten Braun. (2024). Venetoclax Combined with Intensive Chemotherapy: A New Hope for Refractory and/or Relapsed Acute Myeloid Leukemia?. Journal of Clinical Medicine. 13(2). 549–549. 1 indexed citations

Rahmé, Ramy, Valérie Vidal, Thomas Hueso, et al.. (2023). Treatment of Adverse-Risk and Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients with FLAG-IDA ± Venetoclax and CLAG-M: A Monocentric Experience. Blood. 142(Supplement 1). 1520–1520. 2 indexed citations

Rahmé, Ramy, Thorsten Braun, James J. Manfredi, & Pierre Fenaux. (2023). TP53 Alterations in Myelodysplastic Syndromes and Acute Myeloid Leukemia. Biomedicines. 11(4). 1152–1152. 1 indexed citations

Morgan, Gilberto, Evandro de Azambuja, Kevin Punie, et al.. (2021). OncoAlert Round Table Discussions: The Global COVID-19 Experience. JCO Global Oncology. 7(7). 455–463. 6 indexed citations

Maslah, Nabih, Emmanuelle Verger, Pierre Ly, et al.. (2019). Synergistic effects of PRIMA-1^Met (APR-246) and 5-azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia. Haematologica. 105(6). 1539–1551. 100 indexed citations

Sébert, Marie, Marie Passet, Anna Raimbault, et al.. (2019). Germline DDX41 mutations define a significant entity within adult MDS/AML patients. Blood. 134(17). 1441–1444. 123 indexed citations

Esnault, Cécile, Ramy Rahmé, Kim L. Rice, et al.. (2019). FLT3-ITD impedes retinoic acid, but not arsenic, responses in murine acute promyelocytic leukemias. Blood. 133(13). 1495–1506. 32 indexed citations

10.

Jacoby, Meagan A., Eric J. Duncavage, Christopher A. Miller, et al.. (2018). Exome analysis of treatment‐related AML after APL suggests secondary evolution. British Journal of Haematology. 185(5). 984–987. 1 indexed citations

11.

Sébert, Marie, Marie Passet, Anna Raimbault, et al.. (2018). Clinical and Molecular Characteristics of DDX41-Mutated Patients in a Large Cohort of Sporadic MDS/AML. Blood. 132(Supplement 1). 797–797. 1 indexed citations

12.

Rahmé, Ramy & Lionel Adès. (2018). An update on treatment of higher risk myelodysplastic syndromes. Expert Review of Hematology. 12(1). 61–70.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact